Literature DB >> 23634254

CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

Stacey J Baker1, E Premkumar Reddy.   

Abstract

The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell prepares to initiate DNA synthesis. Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer. This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small molecule inhibitors of CDK4 can be used to treat disease.

Entities:  

Keywords:  CDK4; cancer; cell cycle; knockout; targeted therapy

Year:  2012        PMID: 23634254      PMCID: PMC3636745          DOI: 10.1177/1947601913478972

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  159 in total

1.  C-terminal sequences direct cyclin D1-CRM1 binding.

Authors:  Sharon Benzeno; J Alan Diehl
Journal:  J Biol Chem       Date:  2004-10-28       Impact factor: 5.157

2.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.

Authors:  Damia Tormo; Aleix Ferrer; Evelyn Gaffal; Jörg Wenzel; Etiena Basner-Tschakarjan; Julia Steitz; Lukas C Heukamp; Ines Gütgemann; Reinhard Buettner; Marcos Malumbres; Mariano Barbacid; Glenn Merlino; Thomas Tüting
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

4.  Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition.

Authors:  A Kato; H Takahashi; Y Takahashi; H Matsushime
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

5.  Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.

Authors:  N A Hibberts; D J Simpson; J E Bicknell; J C Broome; P R Hoban; R N Clayton; W E Farrell
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 6.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

7.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

8.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation.

Authors:  Enbo Liu; Xianghong Li; Feng Yan; Qiping Zhao; Xiaohua Wu
Journal:  J Biol Chem       Date:  2004-03-05       Impact factor: 5.157

10.  Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice.

Authors:  Elke Hacker; H Konrad Muller; Nicole Irwin; Brian Gabrielli; Douglas Lincoln; Sandra Pavey; Marianne Broome Powell; Marcos Malumbres; Mariano Barbacid; Nicholas Hayward; Graeme Walker
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

View more
  64 in total

Review 1.  CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.

Authors:  Camelia Billard-Sandu; Yun-Gan Tao; Marie-Paule Sablin; Gabriela Dumitrescu; David Billard; Eric Deutsch
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-11       Impact factor: 2.503

2.  CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.

Authors:  Mary E Olanich; Wenyue Sun; Stephen M Hewitt; Zied Abdullaev; Svetlana D Pack; Frederic G Barr
Journal:  Clin Cancer Res       Date:  2015-03-25       Impact factor: 12.531

3.  Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells.

Authors:  Changhe Zhang; Xiaofei Cao; Yongxiang Gei; Yong Wang; Guiyuan Liu; Guochang Cheng; Qinghong Liu
Journal:  Oncol Lett       Date:  2015-07-02       Impact factor: 2.967

Review 4.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

5.  Effects of nitrogen-doped multi-walled carbon nanotubes compared to pristine multi-walled carbon nanotubes on human small airway epithelial cells.

Authors:  Amy L Mihalchik; Weiqiang Ding; Dale W Porter; Colleen McLoughlin; Diane Schwegler-Berry; Jennifer D Sisler; Aleksandr B Stefaniak; Brandi N Snyder-Talkington; Rodolfo Cruz-Silva; Mauricio Terrones; Shuji Tsuruoka; Morinobu Endo; Vincent Castranova; Yong Qian
Journal:  Toxicology       Date:  2015-03-20       Impact factor: 4.221

Review 6.  Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Authors:  Debu Tripathy; Aditya Bardia; William R Sellers
Journal:  Clin Cancer Res       Date:  2017-03-28       Impact factor: 12.531

7.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Authors:  Jeffrey R Infante; Philippe A Cassier; John F Gerecitano; Petronella O Witteveen; Rashmi Chugh; Vincent Ribrag; Abhijit Chakraborty; Alessandro Matano; Jason R Dobson; Adam S Crystal; Sudha Parasuraman; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2016-08-19       Impact factor: 12.531

Review 8.  TGF-β signaling in liver and gastrointestinal cancers.

Authors:  L H Katz; M Likhter; W Jogunoori; M Belkin; K Ohshiro; L Mishra
Journal:  Cancer Lett       Date:  2016-03-30       Impact factor: 8.679

9.  Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions.

Authors:  Yuxin Liu; Morgan Blakely; Keith Sigel; Tin Htwe Thin; Pei Hui; Michael Donovan; Michael M Gaisa
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

10.  Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.

Authors:  Jen-Chieh Lee; Tzu-Pin Lu; Chun A Changou; Cher-Wei Liang; Hsien-Neng Huang; Alexandra Lauria; Hsuan-Ying Huang; Chin-Yao Lin; Ying-Cheng Chiang; Ben Davidson; Ming-Chieh Lin; Kuan-Ting Kuo
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.